Search Result

Isoforms Recommended:	CDK5

Results for "

Cdk5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (86) 17β-HSD (2) 5-HT Receptor (1) Akt (1) Amyloid-β (3) Apoptosis (18) Aurora Kinase (1) Autophagy (4) Bcl-2 Family (1) c-Myc (1) Casein Kinase (1) Caspase (1) CFTR (1) DNA/RNA Synthesis (2) Dopamine Receptor (1) Drug Isomer (1) DYRK (1) E1/E2/E3 Enzyme (1) Early 2 Factor (E2F) (1) EGFR (1) ERK (1) FAK (1) GSK-3 (26) HSV (2) JAK (2) JNK (2) Ligands for Target Protein for PROTAC (2) Lipoxygenase (1) MEK (2) Mitochondrial Metabolism (1) Molecular Glues (2) mTOR (1) NF-κB (1) P-glycoprotein (1) Parasite (3) PKA (1) PKC (1) PPAR (7) PROTACs (2) Proton Pump (2) Reactive Oxygen Species (ROS) (2) Reference Standards (6) Small Interfering RNA (siRNA) (10) Tau Protein (2) Topoisomerase (1) Trk Receptor (1) VEGFR (1) β-catenin (1)
By Research Areas:	Cancer (62) Cardiovascular Disease (1) Endocrinology (1) Infection (3) Inflammation/Immunology (4) Metabolic Disease (11) Neurological Disease (26)
Oligonucleotides:	Nucleoside Analogs (1) Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (6) siRNAs (10)

104

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10492

Dinaciclib Maximum Cited Publications 54 Publications Verification SCH 727965	CDK Apoptosis	Cancer
Dinaciclib (SCH 727965) is a potent inhibitor of *CDK, with IC₅₀s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9*, respectively .

HY-30237

(R)-Roscovitine 30+ Cited Publications Seliciclib; CYC202	CDK	Neurological Disease Metabolic Disease Cancer
(R)-Roscovitine (Seliciclib) is an orally bioavailable, selective and BBB-permeable *CDKs* inhibitor with IC₅₀s of 0.2 μM, 0.65 μM, and 0.7 μM for *CDK5, Cdc2, and CDK2*, respectively.

HY-10580

GSK 3 Inhibitor IX 15+ Cited Publications 6-Bromoindirubin-3'-oxime; BIO; MLS 2052	GSK-3 CDK Apoptosis	Cancer
GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and *CDK1-cyclinB* complex with IC₅₀s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.

HY-10012

AZD-5438 10+ Cited Publications	CDK	Cancer
AZD-5438 is a potent *CDK1, CDK2, and CDK9* inhibitor, with IC₅₀s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .

HY-103712A

Samuraciclib hydrochloride 10+ Cited Publications CT7001 hydrochloride; ICEC0942 hydrochloride	CDK Apoptosis	Cancer
Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .

HY-18340

(R)-CR8 1 Publications Verification CR8, (R)-Isomer	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8, a second-generation analog of Roscovitine, is a potent *CDK1/2/5/7/9* inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect . (R)-CR8 acts as a molecular glue degrader that depletes cyclin K .

HY-144117

GFB-12811	CDK	Metabolic Disease
GFB-12811 is a high selective *CDK5* inhibitor with an IC₅₀ of 2.3 nM .

HY-12302

Kenpaullone 10+ Cited Publications 9-Bromopaullone; NSC-664704	CDK GSK-3	Cancer
Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC₅₀s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC₅₀s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.

HY-103712

Samuraciclib 10+ Cited Publications CT7001; ICEC0942	CDK Apoptosis	Cancer
Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 μM. Samuraciclib has anti-tumor effects .

HY-108359

Alsterpaullone 1 Publications Verification 9-Nitropaullone; NSC 705701	CDK GSK-3 Apoptosis	Cancer
Alsterpaullone (9-Nitropaullone) is a potent *CDK* inhibitor, with IC₅₀s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and *CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC₅₀s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis* in leukemia cell line .

HY-18299A

Purvalanol A 4 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent *CDK* inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-19807

Indirubin-3'-monoxime 4 Publications Verification Indirubin-3'-oxime	GSK-3 CDK Lipoxygenase	Cancer
Indirubin-3'-monoxime is a potent GSK-3β inhibitor, and weakly inhibits *5-Lipoxygenase, with IC₅₀s of 22 nM and 7.8-10 µM, respectively; Indirubin-3'-monoxime also shows inhibitory activities against CDK5/p25* and CDK1/cyclin B, with IC₅₀s of 100 and 180 nM.

HY-15504A

RGB-286638 free base 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a *CDK* inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and *p35-CDK5* with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-11009

CGP60474 5+ Cited Publications	CDK PKC	Cancer
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC₅₀ values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .

HY-15504

RGB-286638 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a *CDK* inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and *p35-CDK5* with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-123772

CDK5 inhibitor 20-223 1 Publications Verification CP668863	CDK	Cancer
CDK5 inhibitor 20-223 is a potent *CDK2* and *CDK5* inhibitor with IC₅₀s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent .

HY-P10440

Cdk5i peptide	CDK	Neurological Disease
Cdk5i peptide is a *CDK5* inhibitory peptide with high binding affinity for Cdk5/p25 (K_d of 0.17 μM), which can block the interaction between CDK5 and p25 and reduce the kinase activity of CDK5/p25. Cdk5i peptide can be used in the stud y of neurodegenerative diseases .

HY-12483

SR1664	PPAR	Metabolic Disease
SR1664 is a PPARγ antagonist. SR1664 binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC₅₀=80 nM; K_i= 28.67 nM) .

HY-18299

Purvalanol B 2 Publications Verification NG 95	CDK Parasite	Infection Cancer
Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor *CDK, with IC₅₀s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively. Purvalanol B shows selectivity for CDK* over a range of other protein kinases (IC₅₀>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum .

HY-108348

BML-259	CDK	Neurological Disease
BML-259 is a potent cyclin-dependent kinase 5 *(Cdk5)* inhibitor, with IC₅₀s of 64 and 98 nM for Cdk5 and Cdk2, respectively .

HY-162683

(S)-PHA533533	CDK E1/E2/E3 Enzyme	Neurological Disease
(S)-PHA533533 is a *CDK2* and *CDK5* inhibitor with blood-brain barrier permeability, with IC₅₀ values of 37 nM and 55 nM, respectively. (S)-PHA533533 effectively restores UBE3A expression by downregulating UBE3A-ATS and relieving the epigenetic silencing of paternal UBE3A in mature neurons. (S)-PHA533533 can be used for the research of Angelman syndrome .

HY-111254

GQ-16	PPAR NF-κB JNK	Inflammation/Immunology
GQ-16 is an orally active PPARγ partial agonist with an IC₅₀ of 1.84 μM and a K_i of 160 nM against human PPARγ. GQ-16 inhibits Cdk5-mediated Ser-273 phosphorylation. GQ-16 improves insulin sensitivity and glucose tolerance in obese and diabetic mice. GQ-16 also exhibits certain cytotoxicity against tumor cells. GQ-16 can be used in research related to obesity, diabetes and cancer .

HY-145694

CDK5-IN-3	CDK	Others
CDK5-IN-3 (compound 11) is a potent *CDK5* inhibitor, with IC₅₀s of 0.6 nM and 18 nM for *CDK5/p25* and *CDK2/CycA, respectively. CDK5-IN-3* can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .

HY-111930

5-Iodo-indirubin-3'-monoxime	GSK-3 CDK	Cancer
5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, *CDK5/P25* and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC₅₀s of 9, 20 and 25 nM, respectively .

HY-121035

7BIO 7-Bromoindirubin-3-Oxime	CDK GSK-3	Neurological Disease
7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice ^[1].

HY-150082

CP681301	CDK DNA/RNA Synthesis	Cancer
CP681301 is a potent *CDK5* inhibitor. CP681301 shows antiproliferative activity. CP681301 decreases the expression of CD133, OLIG2, SOX2, KI67, pCDK5 protein level in GSCs (Glioma stem cells). CP681301 reduces self-renewal in mouse glioma xenografts. CP681301 shows anti-tumor activity in Drosophila .

HY-151071

TMX-3013	Ligands for Target Protein for PROTAC CDK	Cancer
TMX-3013 is a *CDK* inhibitor capable of inhibiting the activity of CDK1, CDK2, CDK4, CDK5, and CDK6, with IC₅₀ values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM, respectively. TMX-3013 can be used as a target protein ligand, conjugated with the PROTAC linker and the CRBN ligand Thalidomide (HY-14658) for the synthesis of PROTAC TMX-2138 (HY-164906). TMX-3013 can also act as an effector ligand, binding to target proteins HaloTag or FKBP, and can be used in the synthesis of regulated induced proximity targeting chimeras (RIPTACs) .

HY-136726

CGP-82996 CINK4	CDK	Cancer
GP-82996 (CINK4) is a pharmacological inhibitor of *CDK4/6. GP-82996 has IC₅₀s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis* of cancer cells U2OS. GP-82996 can be used in the research of cancer .

HY-155218

TMX-2172	PROTACs CDK	Cancer
TMX-2172 is a selective bivalent cereblon-recruiting PROTAC-based dual *CDK2* and *CDK5* degrader with IC₅₀ values of 6.5 nM and 6.8 nM, respectively. TMX-2172 shows selectivity for CDK2 and CDK5 over other cell cycle CDKs (CDK1, CDK4, and CDK6) and transcriptional CDKs (CDK7 and CDK9). TMX-2172 inhibits CDK2/CDK5 enzymatic activity, induces their proteasomal degradation, reduces ASCL1 protein levels and half-life, induces cancer cell death, and exerts antiproliferative effects. TMX-2172 can be used for the research of ovarian cancer and small cell lung cancer ^[5].

HY-145693

CDK5-IN-2	CDK	Others
CDK5-IN-2 (compound 15) is a highly selective *CDK5* inhibitor with IC₅₀s of 0.2 and 23 for CDK5/p25 and CDK2/CycA, respectively .

HY-139725

CDK5-IN-1 1 Publications Verification	CDK	Metabolic Disease
CDK5-IN-1 is a potent *CDK5* inhibitor with an IC₅₀ less than 10 nM. CDK5-IN-1 is greater than 100-fold more active against CDK5 than CDK2. CDK5-IN-1 is used for kidney diseases research .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, *CDK2, and CDK5, with IC₅₀* values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-117025A

Manzamine A hydrochloride 2 Publications Verification Keramamine A hydrochloride	GSK-3 CDK Parasite Proton Pump HSV Autophagy	Infection Neurological Disease Cancer
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and *CDK-5* with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1 .

HY-117025

Manzamine A Keramamine A	GSK-3 CDK Parasite Proton Pump HSV Autophagy	Infection Neurological Disease Cancer
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and *CDK-5* with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1 .

HY-14372

BS-194	CDK	Cancer
BS-194 is an orally active, selective and potent *CDK* inhibitor. BS-194 inhibits CDK2, CDK1, CDK5, CDK7, CDK9 (IC₅₀s: 3, 30, 30, 250, and 90 nM respectively). BS-194 potently inhibits cancer cells proliferation. BS-194 can be used in the research of cancers like breast cancer, colon cancer .

HY-103712C

Samuraciclib hydrochloride hydrate 10+ Cited Publications CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate	CDK Apoptosis	Cancer
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .

HY-103712B

Samuraciclib hydrochloride dihydrate 10+ Cited Publications CT7001 hydrochloride dihydrate; ICEC0942 hydrochloride dihydrate	CDK Apoptosis	Cancer
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .

HY-119715

AG-012986	CDK Apoptosis	Inflammation/Immunology Cancer
AG-012986 is a pan-CDK inhibitor with K_i values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces K_i-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .

HY-112468

PNU112455A hydrochloride	CDK	Cancer
PNU112455A hydrochloride is an ATP-competitive *CDK2* and *CDK5* inhibitor. PNU112455A hydrochloride binds to the ATP site of CDK2 and CDK5 with K_ms of 3.6 and 3.2 μM, respectively .

HY-134622

*GSK-3/CDK5/CDK2-IN-1*	CDK GSK-3	Neurological Disease Cancer
GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of *cdk5, cdk2, and GSK-3* extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases .

HY-103381

NSC693868	CDK GSK-3	Cancer
NSC693868 is a selective inhibitor of *CDK1* and *CDK5* with IC₅₀s of 600 nM and 400 nM, respectively. NSC693868 less potently inhibits GSK3β with an IC₅₀ of 1 µM) and does not block CDC25 activity. NSC693868 is used to help define the roles of CDK1 and CDK5 in various signaling pathways .

HY-114903

(E/Z)-BIO-acetoxime GSK-3 Inhibitor X	GSK-3 CDK	Neurological Disease Metabolic Disease Cancer
(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective GSK-3α/β inhibitor, with an IC₅₀ of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over *CDK5/p25, CDK2/cyclin A and CDK1/cyclin B (IC₅₀*=2.4, 4.3, 63 μM) .

HY-151069

TMX-2039	Ligands for Target Protein for PROTAC CDK	Cancer
TMX-2039 is a *pan-CDK* inhibitor for both cell cycle *CDKs (CDK1,* *CDK2, CDK4, CDK5* and *CDK6) and transcriptional CDKs (CDK7* and *CDK9), with IC₅₀s of 2.6, 1.0, 52.1, 0.5, 35.0, 32.5 and 25 nM, respectively. TMX-2039 acts as a Ligands for Target Protein* for PROTACs .

HY-173347

BLINK11	CDK	Neurological Disease
BLINK11 is a BBB-penetrant *CDK5* inhibitor. BLINK11 lowers CDK5 activity for both complexes *CDK5/p35* (IC₅₀ = 17.09 nM) and *CDK5/p25* (IC₅₀ = 14.69 nM). BLINK11 offers anti-diabetic and neuroprotective benefits. BLINK11 lowers blood glucose, enhances cognition, and reduces neurodegeneration in T2D mice .

HY-13266

BS-181	CDK Apoptosis	Cancer
BS-181 is a potent and selective *CDK7* inhibitor (IC₅₀=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC₅₀ values of 880, 3000 and 4200 nM, respectively (fails to block CDK1, 4 and 6). BS-181 inhibits a panel of cancer cells growth (IC₅₀=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 has the potential for the research of cancer therapy .

HY-RS02385

Cdk5 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk5 Mouse Pre-designed siRNA Set A Cdk5 Mouse Pre-designed siRNA Set A

HY-RS02384

CDK5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
CDK5 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK5 Human Pre-designed siRNA Set A CDK5 Human Pre-designed siRNA Set A

HY-RS02386

Cdk5 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk5 Rat Pre-designed siRNA Set A Cdk5 Rat Pre-designed siRNA Set A

HY-P1906

*[pThr3]-CDK5* Substrate**	CDK	Neurological Disease
[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM .

HY-112336

Aloisine RP106	CDK GSK-3	Neurological Disease
Aloisine RP106 (compound 38) is a potent inhibitor of Cdk1/cyclin B, *Cdk5/p25, and GSK3* with IC₅₀s of 0.70µM, 1.5µM, 0.92 µM, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P10440

Cdk5i peptide	CDK	Neurological Disease
Cdk5i peptide is a *CDK5* inhibitory peptide with high binding affinity for Cdk5/p25 (K_d of 0.17 μM), which can block the interaction between CDK5 and p25 and reduce the kinase activity of CDK5/p25. Cdk5i peptide can be used in the stud y of neurodegenerative diseases .

HY-P2668

Cdk5 Substrate	Peptides	Others
Cdk5 Substrate is a biological active peptide. (substrate for the cdc2 protein kinase)

HY-P1906

*[pThr3]-CDK5* Substrate**	CDK	Neurological Disease
[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM .

HY-P1906A

*[pThr3]-CDK5* Substrate TFA**	CDK	Neurological Disease
[pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM .

Recombinant Proteins Recommended:

Cyclin-Dependent Kinase 5 (CDK5)

Species:	Human (5)
Tag:	SUMO (1) His (4) GST (3) Flag (2)
Source:	sf9 insect cells (1) Sf9 insect cells (2) P. pastoris (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705802

	CDK5 Protein, Human (sf9, GST) Cdk5; Cell division protein kinase 5; Protein kinase Cdk5 splicing; PSSALRE	Human	sf9 insect cells

HY-P72298

	CDK5 Protein, Human (P.pastoris, His) Cdk5; Cell division protein kinase 5; Protein kinase Cdk5 splicing; PSSALRE	Human	P. pastoris
	CDK5 is a proline-directed serine/threonine protein kinase that critically regulates neuronal cell cycle, differentiation and potential apoptosis in neuronal diseases by preventing cell cycle re-entry. It interacts with numerous proteins involved in neuronal development and coordinates processes such as survival, migration, differentiation, axonal growth, synaptogenesis, and neurotransmission. CDK5 Protein, Human (P.pastoris, His) is the recombinant human-derived CDK5 protein, expressed by P. pastoris , with N-His labeled tag.

HY-P704529

	CDK5 Protein, Human (His-SUMO) Cdk5; Cell division protein kinase 5; Protein kinase Cdk5 splicing; PSSALRE	Human	E. coli
	CDK5 is a proline-directed serine/threonine protein kinase that critically regulates neuronal cell cycle, differentiation and potential apoptosis in neuronal diseases by preventing cell cycle re-entry. It interacts with numerous proteins involved in neuronal development and coordinates processes such as survival, migration, differentiation, axonal growth, synaptogenesis, and neurotransmission. CDK5 Protein, Human (His-SUMO) is the recombinant human-derived CDK5 protein, expressed by E. coli, with N-6*His and N-SUMO labeled tag.

HY-P702685

	CDK5-p25 Protein, Human (Active, sf9, GST, His, Flag) Cdk5; cyclin-dependent kinase 5; PSSALRE; TPKII catalytic subunit; protein kinase Cdk5 splicing; cell division protein kinase 5; serine/threonine-protein kinase PSSALRE; tau protein kinase II catalytic subunit;	Human	Sf9 insect cells
	CDK5 is a proline-directed serine/threonine protein kinase that critically regulates neuronal cell cycle, differentiation and potential apoptosis in neuronal diseases by preventing cell cycle re-entry. It interacts with numerous proteins involved in neuronal development and coordinates processes such as survival, migration, differentiation, axonal growth, synaptogenesis, and neurotransmission. CDK5-p25 Protein, Human (sf9, GST, His, Flag) is the recombinant human-derived CDK5-p25, expressed by Sf9 insect cells, with N-GST, N-His, N-Flag labeled tag.

HY-P702686

	CDK5-p35 Protein, Human (Active, sf9, GST, His, Flag) Cdk5; cyclin-dependent kinase 5; PSSALRE; TPKII catalytic subunit; protein kinase Cdk5 splicing; cell division protein kinase 5; serine/threonine-protein kinase PSSALRE; tau protein kinase II catalytic subunit;	Human	Sf9 insect cells
	CDK5 is a proline-directed serine/threonine protein kinase that critically regulates neuronal cell cycle, differentiation and potential apoptosis in neuronal diseases by preventing cell cycle re-entry. It interacts with numerous proteins involved in neuronal development and coordinates processes such as survival, migration, differentiation, axonal growth, synaptogenesis, and neurotransmission. CDK5-p35 Protein, Human (sf9, GST, His, Flag) is the recombinant human-derived CDK5-p35, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (5) Rabbit (3)
Reactivity:	Human (8) Rat (6) Mouse (6) Monkey (4)
Application:	IHC-P (6) ICC/IF (4) IP (3) WB (8) FC (5) ELISA (2)
Isotype:	IgG (3) IgG1 (3)
Conjugation:	Non-conjugated (8)
Clonality:	Monoclonal (6) Recombinant (2)
Modification:	Unmodified (6)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85533

	CDK5(N-term) Antibody (YA5225) Cdk 5; Cdk5; Cdk5_HUMAN; Cell division protein kinase 5; Crk6; Cyclin dependent kinase 5; Cyclin-dependent kinase 5; Protein kinase Cdk5 splicing; PSSALRE; Serine threonine protein kinase PSSALRE; Serine/threonine-protein kinase PSSALRE; Tau protein kinase II catalytic subunit; TPKII catalytic subunit.	WB, ICC/IF	Human, Mouse, Rat, Monkey
	CDK5(N-term) Antibody (YA5225) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CDK5(N-term).

HY-P80078

	CDK5 Antibody (YA512)	WB, IHC-P, FC, IP	Human, Mouse, Rat
	CDK5 Antibody (YA512) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDK5.

HY-P84450

	CDK5 Antibody (YA4147) PSSALRE	WB, IHC-P, ICC/IF, FC, ELISA	Human, Rat, Monkey
	CDK5 Antibody (YA4147) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDK5.

HY-P84450A

	CDK5 Antibody (YA4147)(PBS only) PSSALRE	WB, IHC-P, ICC/IF, FC, ELISA	Human, Rat, Monkey
	CDK5 Antibody (YA4147) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDK5.

HY-P80613

	CDK5 Antibody (YA796) Cdk 5; Cdk5; Cdk5_HUMAN; Cell division protein kinase 5; Crk6; Cyclin dependent kinase 5; Cyclin-dependent kinase 5; Protein kinase Cdk5 splicing; PSSALRE; Serine threonine protein kinase PSSALRE; Serine/threonine-protein kinase PSSALRE; Tau protein kinas	WB, ICC/IF	Human, Mouse, Rat, Monkey
	CDK5 Antibody (YA796) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDK5.

HY-P85693

	CDK5 Antibody (YA5385) Cyclin-dependent kinase 5; Cell division protein kinase 5; Serine/threonine-protein kinase PSSALRE; Tau protein kinase II catalytic subunit; TPKII catalytic subunit;	IHC-P, WB	Human, Mouse, Rat
	CDK5 Antibody (YA5385) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CDK5.

HY-P82183

	CDK5RAP3 Antibody (YA1928) C53; IC53; LZAP; HSF-27; MST016; PP1553; OK/SW-cl.114	WB, IHC-P, FC, IP	Human, Mouse
	CDK5RAP3 Antibody (YA1928) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDK5RAP3.

HY-P82183A

	CDK5RAP3 Antibody (YA1928)(PBS only) C53; IC53; LZAP; HSF-27; MST016; PP1553; OK/SW-cl.114	WB, IHC-P, FC, IP	Human, Mouse
	CDK5RAP3 Antibody (YA1928) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDK5RAP3.